MediGene and Triton Pharma Sign Partnership Agreement for the Commercialization of Veregen® in Canada
MediGene AG /
MediGene and Triton Pharma Sign Partnership Agreement for the Commercialization
of Veregen® in Canada
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Martinsried/Munich, April 19, 2011. The biotech company MediGene AG (Frankfurt,
Prime Standard) has signed an exclusive license and supply agreement with the
Canadian company Triton Pharma Inc. for the supply and commercialization of
Veregen® ointment for the treatment of genital warts in Canada. Triton will be
responsible for the drug approval procedure in Canada. MediGene is entitled to
successive payments totaling up to 2.1 million euros, due upon the achievement
of set milestones, and will obtain royalties on the sales revenue generated with
Veregen® in the form of a double-digit percentage share.
"We are happy that we have found the ideal partner for the commercialization of
Veregen® ointment in Canada. With this agreement and our existing partnerships
with Nycomed and Pierre Fabre, we are now able to serve the entire North and
Central American market." commented Dr. Frank Mathias, Chief Executive Officer
of MediGene AG.
Sybil Dahan, President of Triton Pharma Inc., added: "Triton Pharma is proud to
include MediGene AG on the selective list of European partners fuelling our
product pipeline in Canada. Veregen® is a perfect complement to our current
product portfolio, in line with our focused strategic approach in dermatology,
gynecology and urology."
MediGene has already entered into several marketing partnerships for Veregen®,
e.g. with Nycomed, Inc. for the USA, with Abbott for Germany, Austria, and
Switzerland, with Laboratoires Expanscience for France, and with a number of
other partners across Europe, America, and Asia. MediGene is planning to
continue this global licensing strategy.
Veregen® is currently available on the US, German, and Austrian markets. A
second wave of marketing applications within the European mutual recognition
procedure is planned, with Germany serving as the reference state in this
process.
Veregen®: Veregen® (previously Polyphenon E® ointment) for the topical treatment
of external genital warts is a concentrate of catechins with a complex defined
composition, extracted from green tea leaves. MediGene acquired the basic rights
to the active ingredient in Veregen® from the Canadian company Epitome
Pharmaceuticals, Inc. in 1999, and was solely responsible for the drug's
successful preclinical and clinical development, as well as the approval
process. Patent protection has also been further upgraded by a number of
proprietary inventions. Sinecatechins 15 % ointment (Veregen®) is now also
recommended as a treatment option in the US Department of Health and Human
Services Center for Disease Control and Prevention's the Sexually Transmitted
Diseases Treatment Guidelines 2010 for the treatment of genital warts.
Triton Pharma Inc.: The Canadian Company Triton Pharma, founded in 2005,
specializes in the commercialization of prescription drugs in gynecology
(women's health), urology, and dermatology. With proprietary and licensed
products on the market, the company is successfully positioning itself as the
ideal partner for Companies wishing to establish their products in Canada.
Further information can be obtained at:www.tritonpharma.ca.
This press release contains forward-looking statements representing the opinion
of MediGene as of the date of this release. The actual results achieved by
MediGene may differ significantly from the forward-looking statements made
herein. MediGene is not bound to update any of these forward-looking statements.
MediGene® and Veregen® are registered trademarks of MediGene AG. Polyphenon E®
is a trademark of Mitsui Norin Co., Ltd. These trademarks may be owned or
licensed in select locations only.
- ends -
MediGene AG is a publicly listed (Frankfurt: MDG, prime standard) biotechnology
company headquartered in Martinsried/Munich, Germany. MediGene is the first
German biotech company to have revenues from marketed products. It has various
drug candidates in clinical development and possesses innovative platform
technologies. MediGene focuses on clinical research and development of novel
drugs against cancer and autoimmune diseases.
Contact MediGene AG
Julia Hofmann, Kerstin Langlotz
Investor & Public Relations
Tel.: +49 - 89 - 85 65 - 33 01
Fax: +49 - 89 - 85 65 - 29 20
Email: investor@medigene.com
--- End of Message ---
MediGene AG
Lochhamer Strasse 11 Martinsried / München Germany
WKN: 502090;ISIN: DE0005020903;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
Press release as pdf:
http://hugin.info/132073/R/1507540/442480.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MediGene AG via Thomson Reuters ONE
[HUG#1507540]
